Innate Pharma SA SEC filings IPHYF
Innate Pharma SA has 339 filings in SEC EDGAR's recent list, going back to Jan 31, 2014. Its latest annual report, Form 20-F, was filed on Apr 1, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Nov 5, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Jun 22, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Apr 10, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Mar 4, 2026 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Feb 6, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Oct 21, 2025 | — |
| 144 | Notice of proposed sale | May 30, 2025 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | May 7, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Apr 29, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Apr 29, 2025 | — |
| SC 13D/A | Amended ownership over 5% (active) | Dec 6, 2022 | — |
| SC 13D/A | Amended ownership over 5% (active) | Oct 21, 2022 | — |
| SC 13D | Ownership over 5% (active) | Feb 12, 2021 | — |
| SC 13G | Ownership over 5% (passive) | Feb 3, 2020 | — |
| SC 13D | Ownership over 5% (active) | Oct 25, 2019 | — |
| SC 13G | Ownership over 5% (passive) | Oct 23, 2019 | — |
Showing 15 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- IPHA (Nasdaq), IPHYF (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- France
- Headquarters
- Marseille
- SEC filer status
- Accelerated filer
- SEC CIK
- 1598599
- Former names
- Innate Pharma, SA (until Jan 31, 2014)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.